BRAF and MEK inhibitors lead to increased rates of melanoma cells 'ectopically' expressing PD1, supporting a lymphocyte-independent antitumor effect of anti-PD1 antibody. This provides further rationale for BRAF and MEK inhibitors/anti-PD1 antibody combination therapies in metastatic melanoma patients.
Introduction
Metastatic melanoma is still deadly, despite novel immunomodulatory and protein kinase inhibitor therapies. In preclinical studies, combinations of anti-PD1 antibody and target therapy with BRAF/MEK inhibitors (BRAF/MEKi) had synergistic effects, explained by an increased number and activity of tumor-infiltrating lymphocytes (1, 2) . This increase of tumor-infiltrating lymphocytes following BRAF/MEKi treatment is well documented (3,4), but the tumors may evade the immune system through expression of programmed death-receptor-ligand 1 (PDL1) and 2 (PDL2). These ligands bind and activate the programmed death-receptor 1 (PD1) on T-lymphocytes and suppress the antitumor response (5), while its blockage -by anti-PD1 antibody -restores the antitumor effect.
However, it was suggested that PD1 is 'ectopically' expressed also on melanoma cells, and that its activation could promote tumor growth (6, 7) . The biological relevance of these findings is still not clear,
but PD1
+ melanoma cell subsets were found to preferentially express tumor-initiating determinants (6, 7) . Such putative cancer stem cells could contribute to the development of drug resistance and tumor relapse (8) (9) (10) , which is a main issue for patients treated with BRAF/MEKi (11) (12) (13) . In fact, after an initial rapid anti-tumor response, most patients experience disease progression despite ongoing treatment (11) (12) (13) . Therefore, there is the need to elucidate the relevance of PD1 + melanoma cells during BRAF/MEKi treatment, and to define therapeutic approaches, which could contrast the development of resistance to target therapies.
Here, we evaluate the 'ectopic' melanoma-intrinsic PD1 expression and show that PD1 + and PDL2 + melanoma cells increase during BRAF/MEKi treatment, sensitizing tumor cells to direct anti-PD1
antibody effects, thus delaying the development of resistance to target therapy.
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Author Manuscript Published OnlineFirst on April 12, 2018; DOI: 10.1158/1078-0432.CCR- -derived melanoma cell cultures (mMel2, mMel3, mMel7, mMel11) were generated from surgical biopsies of metastatic/locally advanced melanoma, before any systemic treatment (December 2010 -June 2012). All patients provided consent under institutional review board approved protocols. Technical procedures and melanoma cell cultures were previously described (10, 15) .
Material and Methods

Cancer Cell Line Encyclopedia (CCLE)
Mycoplasma detection was performed by Mycoplasma PCR Detection Kit (Applied Biological Materials Inc., MICROTECH s.r.l. Napoli -Italy) according to the manufacturer's instructions. The test was done after cell thawing/just before the experiment execution. All the experiments were performed on patientderived cell culture of not more than 24 week-old.
Generation of hOct4.eGFP transduced cell lines: The previously described lentiviral vector (14) was transduced in melanoma primary cells resuspended in fresh KODMEM-F12 (Gibco BRL) with 10% FBS adding virus-conditioned medium at a dose of 400 ng P24/100,000 cells. The lentiviral vector pRRL.sin.PPT.hOct4.eGFP.Wpre (LV-Oct4.eGFP) was obtained as previously described (15) .
Briefly, the hOct4-eGFP cassette from phOct4.eGFP1 vector (16) (kind gift from Dr. Wei Cui, IRDB, Imperial College, London) was cloned into the transfer vector pRRL.sin.PPT.hPGK.eGFP.Wpre (17) (kindly provided by Dr. Elisa Vigna, IRCCS Candiolo/University of Turin, Italy) in place of the hPGK.eGFP cassette. After 16 hours, cells were washed twice and grown for a minimum of 10 days to reach steady state eGFP expression and to rule out pseudotransduction before flow cytometry analysis. Technical procedure including transduction controls were previously described (10).
Drugs: The BRAF inhibitor dabrafenib (GSK2118436) and the MEK inhibitor trametinib (GSK1120212) were purchased from Selleckchem. The anti-PD1 antibody is the inVivoMAb antihuman PD1(CD279), Clone: J110 from Bio X Cell. The isotype control antibody is the inVivoMAb mouse IgG1 isotype control, Clone: MOPC-21 from Bio X Cell. Drugs were used accordingly to previous reports (7, 18, 19 Comparisons between two independent non-normally distributed groups were performed using the nonparametric Wilcoxon rank-sum test. Comparisons between matched groups were performed with Wilcoxon signed rank test. Correlations between variables were tested with the Spearman's rank correlation test. Differences in tumor volumes were statistically assessed using repeating measurements two-way ANOVA followed by Sidak correction and with two-tails. P values less than 0.05 were considered statistically significant.
Results
Melanoma cells express low but consistent levels of PD1
To investigate PD1 expression on melanoma cells, we analyzed two datasets: the Cancer Cell Line Encyclopedia (CCLE), and The Cancer Genome Atlas (TCGA). (Fig. 1C) .
From the 470 TCGA patient derived melanomas, we matched gene expression data with corresponding histological reports and we excluded all the samples with histological evidence of immune infiltrate, as those would interfere with the assessment of melanoma-intrinsic PD1 expression (Fig. 1D) . PD1 was expressed in 99.5% of the samples, with a median expression comparable to PDL1 and PDL2 (Fig. 1E) . We did not find significant differences when we compared samples with (N=100) and without (N=114) Fig. 2A) (Fig. 2C, Fig.S2B (Fig. 2D,   Fig.S2C ).
In BRAF V600 mutant cells, the combination of BRAF and MEK inhibitors led to the highest percentage of PD1 + cells, and showed the greatest anti-tumor effect, whilst in the NRAS Q61 mutant cell line this was observed with MEK inhibitor alone (Fig. S3 ). Fotemustine efficiently killed tumor cells, but did not significantly change levels of PD1 + cells (Fig. 2E) .
Rates of PD1 + melanoma cells increase in a time-and drug-dependent manner during BRAF/MEKi treatment
We explored if the percentage of PD1 + melanoma cells was influenced by time or drug exposure. (Fig. 2F, 2G ). Following BRAF/MEKi withdrawal, the rate of PD1 + melanoma cells returned back to the low original value (Fig. 2H, 2I ) (N=3).
PD1 + melanoma cells are more quiescent and present stemness features
Since during BRAF/MEKi treatment PD1 + cells reach significant percentages among the viable tumor cell population, we compared their proliferative capabilities with PD1 -cells. We used a carboxyfluorescein succinimidyl ester (CFSE) dye-based assay, where the dye decrease corresponds to higher mitotic activity and faster proliferation rate. Treatment with BRAF/MEKi decreased the overall proliferation (Fig. 3A) with PD1 + cells proliferating less than the PD1 -counterparts; on average 16.1% less after 96 hours (N=3), and 65% less after 7 days (N=2) (Fig. 3B, Fig. S4 ).
Research. PD1 was reported to be preferentially expressed on putative melanoma cancer stem cells (6) . To test this, we used a lentiviral vector carrying eGFP under the transcriptional control of the Oct4 stemness gene promoter (LV-Oct4.eGFP) (Fig. 3C) (15) . This system visualizes putative cancer stem cells as eGFP + , based on their selective ability to activate the Oct4 promoter. In three LV-Oct4.eGFP transduced patient-derived cell lines (mMel2-Oct4, mMel3-Oct4, mMel7-Oct4), BRAF/MEKi led to overall eGFP + cell enrichment (on average 2.4-fold), suggesting a lower sensitivity of eGFP + melanoma cells to these drugs (Fig. 3D) . Moreover, eGFP + putative cancer stem cells were enriched among PD1 + cells compared to PD1 -cells (on average 1.6-fold) (N=3) (Fig. 3E ).
Anti-PD1 antibody prolongs the antitumor response to BRAF/MEKi
Considering the hypothesis that PD1 activation could lead to melanoma proliferation (7), we tested if PD1-blockage could have a direct anti-tumor effect.
In-vitro, the sole use of anti-PD1 antibody did not affect cell viability (Fig. S5) . When we combined anti-PD1 antibody with BRAF/MEKi we observed only a trend towards a better anti-tumor effect compared to BRAF/MEKi alone during short-term drug exposure (Fig. S6) . To test the hypothesis that the subset of PD1 + melanoma cells, which are preferentially endowed with stemness features, might contribute to the development of BRAF/MEKi resistance, we set up an in-vivo long-term experiment.
We used non-obese diabetic/severe combined immunodeficient (NOD-SCID)/interleukin 2 receptor 'Ectopic' melanoma-intrinsic PD1 expression and its possible role in promoting tumor growth were proposed (7), but the biological relevance of these findings is still not clear. Such subsets were observed to have tumor-initiating properties; thus, they could contribute to the development of drug resistance.
We first chose an in-vitro platform to characterize melanoma-intrinsic PD1 expression in normal conditions and during BRAF/MEKi treatment. We confirmed that melanoma cells do express In-vitro, the addition of anti-PD1 antibody to BRAF/MEKi, only slightly improved their anti-tumor effects, and only when used at higher dose (100 g/ml) than previously described in melanoma (50 g/ml) (7). Considering the negligible in-vitro effect, we did not further investigate possible off-target Differently from previously published findings in the same mouse model (7), anti-PD1 antibody alone did not affect melanoma tumor growth in our hands. This difference can be due to the very low rates of marked by the arrow. Statistical analysis was carried out using two-way ANOVA followed by Sidak correction and with two-tails. *p<0.05; ***p<0.001)
